Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
|Videos|November 11, 2021
The Role of Setting in Patient Care During the Treatment of Burkitt Lymphoma
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the role setting has in the care of patients with Burkitt lymphoma.
Advertisement
Pharmacy Times interviewed Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, to discuss his SOHO 2021 conference presentation on prognostication and treatment of Burkitt lymphoma in the modern era.
During the interview, Olszewski discussed the role setting has in the care of patients with Burkitt lymphoma.
Advertisement
Related to this article
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.
Advertisement
Advertisement